Protecting a blockbuster diabetes treatment for AstraZeneca
AstraZeneca AB
Major victories across IP venues for Volkswagen, Audi, Bentley, and Lamborghini
Audi AG; Audi of America, LLC; Automobili Lamborghini America, LLC; Automobili Lamborghini S.p.A.; Bentley Motors Limited; Bentley Motors, Inc; Volkswagen AG; Volkswagen Group of America, Inc.
No confusion in trademark victory on summary judgment for the American Retirement Association
American Retirement Association
Finnegan helps Intellia Therapeutics acquire Rewrite Therapeutics, Inc. for $45 million
Intellia Therapeutics, Inc.
Finnegan secures favorable ITC ruling related to innovative electric SUVs for BMW
BMW of North America, LLC and Bayerische Motoren Werke AG
Finnegan fights for Sony’s “exceedingly famous” mark
Sony Group Corporation
Experience
Eli Lilly and Company v. Genentech, Inc. Eli Lilly and Company v. Genentech, Inc.
PGR2019-00043, PTAB, Judges Mitchell, Paulraj, Cotta
3:18-cv-01518, S.D. Cal., Judge Sammartino
Experience
Eli Lilly and Company v. Teva Pharmaceuticals USA, Inc. Eli Lilly and Company v. Teva Pharmaceuticals USA, Inc.
1:16-cv-00596, S.D. Ind., Judges Pratt, Brookman
Experience
Alzheimer's Institute of America, Inc. v. Avid Radiopharmaceuticals Alzheimer's Institute of America, Inc. v. Avid Radiopharmaceuticals
2:10-cv-06908, E.D. Pa., Judges Angell, Savage, Cohen (Special Master)
13-1544, 16-2647, Fed. Cir., Judges Hughes, Lourie, Moore, Newman, Plager
Experience
Lannett Holdings, Inc. v. AstraZeneca AB Lannett Holdings, Inc. v. AstraZeneca AB
IPR2015-01629, -01630, PTAB
Experience
Alzheimer's Institute of America, Inc. v. Eli Lilly and Company Alzheimer's Institute of America, Inc. v. Eli Lilly and Company
3:10-cv-00482, N.D. Cal., Judges Breyer, James, Laporte
Experience
Federal Circuit reverses district court ruling of invalidity and upholds rulings on other grounds in favor of Finnegan client Eli Lilly and Co. Federal Circuit reverses district court ruling of invalidity and upholds rulings on other grounds in favor of Finnegan client Eli Lilly and Co.
10-1500, -1520, -1521, -1522, -1523, -1524, Fed. Cir., Judges Lourie, Newman
2:07-cv-03770, D.N.J., Judges Cavanaugh, Dickson, Falk
Experience
Eli Lilly and Co. wins challenge to patents covering its osteoporosis drug, Evista® Eli Lilly and Co. wins challenge to patents covering its osteoporosis drug, Evista®
1:06-cv-01017, S.D. Ind., Judges Barker, Magnus-Stinson
09-1071; 10-1005, -1033, Fed. Cir., Judges Linn, Michel, Prost, Rader
Experience
When the patent for Zyprexa® and $2 billion in annual revenue were on the line, Eli Lilly turned to Finnegan When the patent for Zyprexa® and $2 billion in annual revenue were on the line, Eli Lilly turned to Finnegan
1:01-cv-00443, S.D. Ind., Judges LaRue, Lynch, Shields, Young
05-1429, -1430, Fed. Cir., Judges Rader, Schall, Gajarsa
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.